Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Protein Kise C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Overview
Protein Kise C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Protein Kise C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Protein Kise C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Companies Involved in Therapeutics Development
BryoLogyx Inc
CHS Pharma Inc
Syptogenix Inc
VM Discovery Inc
Young Therapeutics LLC
Protein Kise C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Drug Profiles
Protein Kise C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Dormant Products
Protein Kise C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Discontinued Products
Protein Kise C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Product Development Milestones
Featured News & Press Releases
Jul 26, 2022: Syptogenix announces changes to scientific advisory board in preparation for phase 2 data
Jul 20, 2022: Syptogenix advances dosing of first patient in dose optimization clinical trial in preparation for NIH-sponsored, phase 2 Alzheimer’s disease trial data
Apr 20, 2022: Syptogenix concludes subject enrolment in Phase IIb Alzheimer’s trial
Apr 05, 2022: New peer reviewed article demonstrates extended therapeutic potential of Syptogenix’s Bryostatin for Alzheimer’s disease
Mar 22, 2022: Syptogenix to present at Sachs 5th Annual Neuroscience Innovation Forum
Mar 15, 2022: Syptogenix to present research highlighting potential broad applicability for lead compound bryostatin at the Intertiol Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022)
Feb 23, 2022: Syptogenix moves forward with clinical development plans for Bryostatin-1 as a treatment for multiple sclerosis
Feb 01, 2022: Syptogenix announces publication of peer-reviewed scientific article evidencing Byrostatin-1’s improved cognition over baseline in advanced Alzheimer’s Disease patients
Jul 26, 2021: Syptogenix discloses positive results of further Bryostatin trial alyses in presentation at Alzheimer’s Association Intertiol Conference 2021
Jul 14, 2021: Syptogenix to present data at Alzheimer’s Association Intertiol Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline
Jul 07, 2021: Syptogenix announces regenerative patent award to treat Alzheimer’s disease
Jun 09, 2021: Syptogenix announces phase 2b NIH sponsored Alzheimer’s disease trial update
Apr 01, 2021: Syptogenix announces phase 2b Bryostatin-1 clinical trial update
Feb 04, 2021: Synthetic bryostatin available to expand neurodegenerative indication trials
Oct 13, 2020: BryoLogyx announces completion of world’s first GMP synthesis of bryostatin-1
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by BryoLogyx Inc, 2022
Pipeline by CHS Pharma Inc, 2022
Pipeline by Synaptogenix Inc, 2022
Pipeline by VM Discovery Inc, 2022
Pipeline by Young Therapeutics LLC, 2022
Dormant Projects, 2022
Discontinued Products, 2022